Loading stock…

Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. (600436) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Zhangzhou Pientzehuang Pharmaceutical Co., Ltd.

600436Market cap $11BPrice $17.5

Country🇨🇳China

SectorHealthcare

IndustryPharmaceuticals

Makes traditional Chinese medicine, most famously Pien Tze Huang, a centuries-old herbal formula guarded like a state secret. The recipe is one of only two in China legally protected as classified — rarer than Coca-Cola's.

In Bastion Portfolios?

52W Return-37%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+1%3

Revenue Forecast

Rev CAGR (1y)-6%1

Rev CAGR (3y)+2%2

Rev CAGR (5y)+8%7

Earnings Forecast

EPS Growth Y+1+8%6

EPS Growth Y+2+16%8

EPS Growth Y+3+22%8

Quality

Margins

EBIT Margin21%8

Net Income Margin22%8

Free Cash Flow Margin9%6

Debt

Net Debt/EBITDA-1.410

Efficiency

ROE12%6

ROA10%8

Earnings Stability55

GEAR+AVERAGE51

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)372

P/E Ratio (Forward 3y)222

P/BV4.93

EV Multiples

EV/EBITDA Fwd272

EV/EBIT Fwd282

Yield

Free Cash Flow Yield1.1%3

Dividend Yieldna–

Momentum

Short term

1 month return-4%5

3 month return+7%8

YTD return-29%1

Mid term

Price vs 52wHigh60%2

1 year return-39%1

Long term

3 year return-55%1

5 year return-69%1

Risk Shield

Price Risk

Beta-0.210

Volatility29%7

Free Cash Flow

Free Cash Flow Margin9%6

Free Cash Flow Yield1.1%3

Quality

ROCE11%6

Earnings Stability55

Net Debt/EBITDA-1.410

02Growth

Is it actually growing, and how fast?

600436Zhangzhou Pientzehuang Pharmaceutical Co.

Revenue FY25$1.3B

GROWTH RATING↗

WEAK29 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+1%3

Revenue, next 1Y-6%1

Revenue, next 3Y, CAGR+2%2

Revenue, next 5Y, CAGR+8%7

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+8%6

EPS growth, FY27E+16%8

EPS growth, FY28E+22%8

GROWTH ASSESSMENT

STRENGTHS

The runway holds up: revenue is set to grow 8%/yr over five years.7/10

Earnings are set to grow faster than sales (EPS about 16%/yr vs revenue 2%/yr), so margins should widen.

WATCH

Revenue grew 0.7%/yr over the last 3 years and is set to keep growing around 2%/yr.

WEAKNESSES

Growth is the weak spot here, trailing 71% of companies worldwide.

Revenue grew 0.7%/yr over the last 3 years, behind 70% of companies worldwide.3/10

Revenue is set to grow 2%/yr over the next 3 years, behind most of the market.3/10

BOTTOM LINE

Margin Expander

Growth is a weak point here. The one thing to watch: the 3-year revenue record is weak.

03Price Momentum

Is the market behind it right now?

600436Zhangzhou Pientzehuang Pharmaceutical Co.

Total return Current185%

Price return Current165%

MOMENTUM RATING↗

VERY WEAK14 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-4%5

3-month return+7%8

YTD return-29%1

MID & LONG-TERM▾SCORE

% of 52-week high60%2

1-year return-39%1

3-year return-55%1

5-year return-69%1

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming over three months (+7%).

WATCH

Returns sit at the market level over the past month (-4%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-55% over three years and -69% over five), behind 90% of the market.

It's down 39% over the past year, now 40% below its 52-week high. That is lagging the market.

The stock is underperforming so far this year (-29%).

BOTTOM LINE

Weak Tape

Returns across short and long horizons rank poorly versus the market. Momentum offers no support here; the case has to come from other factors. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Zhangzhou Pientzehuang Pharmaceutical Co., Ltd.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

600436Zhangzhou Pientzehuang Pharmaceutical Co.

Revenue FY25$1.3B

GROWTH RATING↗

WEAK29 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+1%3

Revenue, next 1Y-6%1

Revenue, next 3Y, CAGR+2%2

Revenue, next 5Y, CAGR+8%7

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+8%6

EPS growth, FY27E+16%8

EPS growth, FY28E+22%8

GROWTH ASSESSMENT

STRENGTHS

The runway holds up: revenue is set to grow 8%/yr over five years.7/10

Earnings are set to grow faster than sales (EPS about 16%/yr vs revenue 2%/yr), so margins should widen.

WATCH

Revenue grew 0.7%/yr over the last 3 years and is set to keep growing around 2%/yr.

WEAKNESSES

Growth is the weak spot here, trailing 71% of companies worldwide.

Revenue grew 0.7%/yr over the last 3 years, behind 70% of companies worldwide.3/10

Revenue is set to grow 2%/yr over the next 3 years, behind most of the market.3/10

BOTTOM LINE

Margin Expander

Growth is a weak point here. The one thing to watch: the 3-year revenue record is weak.

03Price Momentum

Is the market behind it right now?

600436Zhangzhou Pientzehuang Pharmaceutical Co.

Total return Current185%

Price return Current165%

MOMENTUM RATING↗

VERY WEAK14 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-4%5

3-month return+7%8

YTD return-29%1

MID & LONG-TERM▾SCORE

% of 52-week high60%2

1-year return-39%1

3-year return-55%1

5-year return-69%1

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming over three months (+7%).

WATCH

Returns sit at the market level over the past month (-4%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-55% over three years and -69% over five), behind 90% of the market.

It's down 39% over the past year, now 40% below its 52-week high. That is lagging the market.

The stock is underperforming so far this year (-29%).

BOTTOM LINE

Weak Tape

Returns across short and long horizons rank poorly versus the market. Momentum offers no support here; the case has to come from other factors. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Zhangzhou Pientzehuang Pharmaceutical Co., Ltd.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community